A股港股医药表现不同，原因是啥？｜第432期直播回放

Group 1 - The pharmaceutical industry has various sub-sectors, with the most funds allocated to three main areas: healthcare, biotechnology, and innovative drugs [3][16] - The healthcare sub-sector includes medical services and medical devices, such as hospitals and equipment like pacemakers and syringes [4][5][6] - The biotechnology sub-sector focuses on companies in gene diagnostics, biopharmaceuticals, blood products, and human biotechnology, including vaccines [7][8][9] - The innovative drugs sub-sector is primarily related to pharmaceuticals, with many companies involved in both biotechnology and innovative drugs [10][11] Group 2 - Over the past 20 years, the A-share pharmaceutical industry has experienced six cycles of bull and bear markets, with the latest cycle starting in 2024 [18][19] - The A-share pharmaceutical index has shown limited growth recently, underperforming compared to the broader market, while the Hong Kong pharmaceutical index has significantly outperformed the Hang Seng Index [22][24] - The differences in performance between A-share and Hong Kong pharmaceutical sectors are attributed to variations in fundamentals and valuations [25][26] Group 3 - The A-share pharmaceutical sector is currently in a recovery phase, with a modest year-on-year profit growth of a few percent, while the Hong Kong pharmaceutical sector is in a boom phase with strong profit recovery [41][43] - Investment in the pharmaceutical industry should focus on undervalued opportunities, with a recommendation to buy during low valuation periods and hold until high valuation [46][48] - It is advised to limit exposure to individual industry or thematic investments to 15-20% for stability [49]